Pharmafile Logo
Pharmafocus logo
Advanced Search

Nexavar

Showing 15 posts of 20 posts found.

NICE recommends thyroid cancer drug trio for NHS use

February 20, 2018
Manufacturing and Production, Sales and Marketing Bayer, Cancer, Cometriq, Eisai, Lenvima, NICE, Nexavar, ipsen, pharma, thyroid cancer

NICE has announced its decision to recommend that three separate treatments for thyroid cancer should be made available for use …

News

Bayer’s liver cancer drug availability spreads to UK with NICE approval

August 10, 2017
Sales and Marketing Bayer, Cancer, NICE, Nexavar, life sciences, liver cancer, pharma, pharmaceutical

NICE has announced that it has given final appraisal recommending Bayer’s Nexavar (sorafenib) for the treatment of advanced hepatocellular carcinoma …

News

Bayer’s liver cancer drug not cost-effective, says NICE

August 19, 2016
Medical Communications, Sales and Marketing Bayer, CDF, NICE, Nexavar, lung cancer

NICE has deemed Bayer’s liver cancer drug Nexavar (sorafenib) as not cost-effective. The drug is currently available on the Cancer …

News
bayer_healthcare

Mixed results for new leukaemia drugs

December 9, 2014
Research and Development, Sales and Marketing AML, Bayer, Nexavar, Qinprenzo, Sunesis Pharmaceuticals, sorafenib

Two trials of new drugs for acute myeloid leukaemia (AML) have shown promising results in younger and older groups of …

News
nexavar image

US regulator shows Nexavar green light

November 25, 2013
Sales and Marketing Bayer, Cancer, FDA, Nexavar, Onyx, thyroid

The FDA has extended the indication of liver and kidney cancer pill Nexavar to treat late-stage differentiated thyroid cancer. It …

News
bayer_cross_2

Nexavar gains FDA ‘speed lane’ status for thyroid cancer

August 28, 2013
Research and Development, Sales and Marketing Amgen, Nexavar, Onyx

News
Roche building

Roche abandons Herceptin patents in India

August 19, 2013
Medical Communications, Sales and Marketing Biocon, GSK, Herceptin, India, Nexavar, Roche, biosimilar

News
votrient image

Survival boost for Votrient in mRCC

October 2, 2012
Research and Development, Sales and Marketing GSK, Nexavar, Pfizer, Sutent, Votrient

GlaxoSmithKline’s renal cell carcinoma drug Votrient has proved itself non-inferior to a bitter rival, Pfizer’s Sutent, in terms of progression-free …

News

Bayer raises guidance after strong sales

July 31, 2012
Sales and Marketing Bayer, Nexavar, Q2, Xarelto, Yasmin

The Bayer Group has raised its full-year guidance for 2012 following positive results in the second quarter. This is despite …

News
Nexavar image

Torisel fails in head-to-head study with Nexavar

May 16, 2012
Research and Development, Sales and Marketing Bayer, Nexavar, Pfizer, Torisel, inlyta, rcc

Pfizer’s kidney cancer drug Torisel has failed to best Bayer’s Nexavar in a head-to-head trial.  The Phase III study was …

News

FDA approves Pfizer cancer drug Inlyta

January 30, 2012
Sales and Marketing Nexavar, Pfizer, Sutent, rcc, renal cell carcinoma

Pfizer’s kidney cancer drug Inlyta has gained US approval for second line treatment for the disease. Inlyta (axitinib) is now …

News
Pfizer HQ

Pfizer files new kidney cancer drug

June 2, 2011
Sales and Marketing Nexavar, Pfizer, rcc

Pfizer has filed its kidney cancer drug axitinib in the EU after impressive head-head- trials with Bayer’s Nexavar. Pfizer is …

News
Bayer's Marijn Dekkers

Bayer goes for pharma growth

March 1, 2011
Research and Development, Sales and Marketing 2010 pharma results, Bayer, Dr Jörg Reinhardt, Marijn Dekkers, Nexavar, VEGF Trap-Eye, Xarelto

While many of its larger peers in the pharma sector are rushing to diversify into consumer health and generics, Bayer, …

Feature

Pfizer’s axitinib impresses in head-to-head trial with Nexavar

November 22, 2010
Research and Development, Sales and Marketing Kidney cancer, Nexavar, Pfizer, axitinib, mRCC, metastatic renal cell carcinoma

Pfizer’s axitinib has impressed in phase III trials assessing its efficacy as a second line treatment for renal cell carcinoma. …

News

Nexavar fails in lung cancer trial

June 15, 2010
Research and Development Bayer, NSCLC, Nexavar, Onyx

Bayer and Onyx Pharmaceutical’s oncology drug Nexavar has failed to meet its primary endpoint in a phase III study for …

News

Latest content

Sanofi shares results for phase 3 LUNA 3 trial in immune thrombocytopenia

April 23, 2024

FDA approves ImmunityBio’s Anktiva bladder cancer treatment

April 23, 2024

EC approves Pfizer’s Emblaveo for multidrug-resistant infection treatment

April 22, 2024

Neurolentech and Kaerus Bioscience enter partnership for research on neurodevelopmental disorder

April 22, 2024

Ardena announces €20m expansion following first GMP approval

April 19, 2024